Introduction
============

Bilirubin belongs to the superfamily of tetrapyrrolic compounds, which is one of the most highly conserved groups of molecules in nature. Tetrapyrroles have evolved to have pluripotent functions, including light harvesting in plants; as well as other roles in plants as well as in humans: chronobiology, energy generation, transport, and homeostasis of oxygen by hemoglobins and myoglobin -- to mention only a few of them. Although for decades bilirubin was believed to be a potentially toxic metabolite of heme catabolism, in particular for central nervous system, data from the last few decades clearly demonstrates that this tetrapyrrolic compound might also have numerous other beneficial effects for the human body, including the scavenging of overproduced reactive oxygen species, anti-inflammatory actions, or direct effects upon cell signaling.

Bilirubin is the end product of heme catabolism in the systemic circulation. It is formed by the action of heme oxygenase (HMOX), an enzyme that splits cyclic tetrapyrrole heme into biliverdin, carbon monoxide, and ferrous iron. Biliverdin is subsequently reduced to bilirubin by biliverdin reductase (BLVRA). HMOX exists in two isoforms: HMOX1, a highly inducible isoform responsible for reactions of acute phase immediate response against oxidative stress, and a constitutive isoenzyme HMOX2, playing important roles in the brain and testes. The third member of the HMOX family (*HMOX3*) has also been described, but it is generally believed that *HMOX3* is only represented by a pseudogene, with no coding function (Hayashi et al., [@B24]). Nevertheless, in light of the recent discoveries of the possible regulating functions of pseudogenes (Pink et al., [@B65]), it is possible that *HMOX3* might also have biological effects by contributing to gene regulation.

Bilirubin, as a non-polar molecule, is solubilized in the vascular bed by binding to albumin. When reaching the liver, it is actively transported by the basolateral OATP transporter, solubilized in the cytoplasm by binding to specific binding proteins, and subsequently conjugated by the action of bilirubin UDP-glucuronosyltransferase (UGT1A1) with two molecules of glucuronic acid. Bisglucuronosyl bilirubin is then actively secreted into bile and proceeds into the intestinal lumen, where it undergoes further metabolic changes. From the metabolic point of view, there are several crucial enzymatic steps (in particular those catalyzed by HMOX1, BLVRA, and UGT1A1 enzymes) which play an important role in bilirubin homeostasis with subsequent impacts on the risk of metabolic diseases, including cardiovascular diseases (CVD), diabetes, metabolic syndrome, arterial hypertension, and obesity.

Serum bilirubin concentrations are affected by many factors including cigarette smoking, gender, fasting, intake of numerous drugs and/or plant products, altitude, race, and age (for review see Vítek and Schwertner, [@B84]). All these factors are likely to influence biological impact of bilirubin on human body.

Biological Properties of Bilirubin
==================================

Bilirubin has been recognized as a substance with potent antioxidant properties. The first report on the antioxidant effects of bilirubin was published as early as 1954 (Bernard et al., [@B7]), however, it took several more decades until the antioxidant properties of bilirubin attracted major scientific attention (Stocker et al., [@B73]). Indeed, bilirubin has been shown to be more effective at protecting lipids from oxidation than the water-soluble antioxidants such as glutathione, which primarily protect proteins from oxidation (Sedlak et al., [@B70]). However, bilirubin has also been demonstrated to be almost 30 times more potent toward the prevention of LDL oxidation compared to a vitamin E analog, Trolox, which represents a lipid-soluble antioxidant substance (Wu et al., [@B88]). Even more importantly, serum bilirubin has been demonstrated to be a major contributor to the total antioxidant capacity in blood plasma (Frei et al., [@B16]). Additionally, bilirubin has been proven to have anti-inflammatory properties (for review see Vítek and Schwertner, [@B84]). Bilirubin inhibited tumor necrosis factor α-induced up-regulation of E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule (ICAM-1) *in vitro* (Mazzone et al., [@B50]). The negative association between serum bilirubin levels and soluble forms of CD40 ligand and P-selectin which have also been demonstrated in *in vivo* study on subjects with Gilbert syndrome (Tapan et al., [@B75]). Bilirubin has also been shown to significantly interfere with the complement system, with all of the possible protective consequences (reviewed in Basiglio et al., [@B6]). Consistent with this data, several studies have demonstrated a negative relationship between serum bilirubin and C-reactive protein levels (Vítek et al., [@B81]; Hwang et al., [@B27]; Yoshino et al., [@B92]). In addition, the modulatory effects of bilirubin on T regulatory cell differentiation were recently reported (Rocuts et al., [@B67]), further underlining the protective role of bilirubin in the pathogenesis of chronic inflammatory as well as in autoimmune conditions.

Negative Association between Bilirubin and Cardiovascular Diseases
==================================================================

The first report of a negative relationship between serum bilirubin levels and coronary artery disease was published as early as 1994 (Schwertner et al., [@B68]). Since then, numerous studies have been published, which have consistently demonstrated that subjects with lower bilirubin levels are at increased risk of both coronary and peripheral atherosclerotic disease (for reviews see recent papers; Vítek and Schwertner, [@B84]; Schwertner and Vítek, [@B69]; Vítek and Ostrow, [@B83]; Lin et al., [@B43]). Serum bilirubin concentrations were also found to be negatively related to coronary artery calcification (Tanaka et al., [@B74]), and also to ischemic stroke (Kimm et al., [@B34]); all consistent with our own data which demonstrated a marked postponement in the progression of the intimo-medial thickness of carotid arteries in hyperbilirubinemic subjects with Gilbert syndrome, when compared to normobilirubinemic individuals (Vítek et al., [@B82]). In addition, our meta-analysis of studies focused on the association between CVD and bilirubin, involving almost 15,000 men, showed that each 1.0 μmol/L increase in serum bilirubin was associated with a 6.5% decrease in CVD risk (Novotný and Vítek, [@B60]). The same association was also reported in a recent Taiwanese prospective study on patients with cardiac X syndrome followed for 5 years, in which patients with the lowest serum bilirubin levels had a higher incidence of non-fatal myocardial infarction, ischemic stroke, rehospitalization for unstable angina, and coronary revascularization procedures (Huang et al., [@B26]).

Logically, the opposite relationship is also true, i.e., subjects with moderately elevated levels of serum bilirubin, such as those with Gilbert syndrome, are at decreased risk of CVD (Vítek et al., [@B80]).

Although the association of serum bilirubin levels and CVD has been known for almost two decades, the relationship between bilirubin and other players of the heme catabolic pathway, as well as pathologic conditions such as metabolic syndrome and/or diabetes has only been investigated in the last few years.

Heme Oxygenase and Diabetes -- Experimental Evidence
====================================================

Diabetes mellitus, the hallmark of which consists of elevated plasma glucose, is consistently associated with increased oxidative stress, as well as enhanced formations of advanced glycation end products (AGEs; Yamagishi et al., [@B90]). Overproduction of oxidizing molecules results in the progressive loss of pancreatic β-cells, depleting insulin levels. However, also numerous other mechanisms contributing to the pathogenesis of diabetes play an important pathogenic role, including reduction of the adiponectin levels (Soares et al., [@B71]), interference with insulin signaling, endothelial dysfunction, or direct damages of the endothelial wall (Unoki and Yamagishi, [@B78]; Potenza et al., [@B66]; Giacco and Brownlee, [@B21]). Thus, it is not surprising that HMOX1, as a key antioxidant enzyme, has consistently been shown to protect from the development of diabetes (for review see Ndisang, [@B54]). The mechanisms by which HMOX1 mediated these effects are pluripotent, and apart from the antioxidant action, HMOX1 also directly affects glucose metabolism, which might be due to the presence of a binding site for a glucocorticoid-responsive element in the *HMOX1* gene promoter (Lavrovsky et al., [@B37]). In fact, HMOX1 was shown to stimulate insulin production in experimental animal models (Ndisang, [@B54]), at least partially, *via* the release of carbon monoxide (Henningsson et al., [@B25]), which is an immediate product of HMOX. Indeed, HMOX1 induction by hemin has been demonstrated to improve insulin signaling and glucose metabolism, and to have lowered insulin resistance in various animal models, including those of streptozotocin-induced diabetes (Ndisang and Jadhav, [@B55]), insulin-resistant type 2 diabetes (Ndisang and Jadhav, [@B56]), primary hyperaldosteronism (Ndisang and Jadhav, [@B57]), as well as essential hypertension (Ndisang et al., [@B58]). Apart from an improvement of insulin sensitivity, HMOX1 induction was also reported to reduce visceral and subcutaneous obesity in diabetic and obese mice (Li et al., [@B42]; Nicolai et al., [@B59]; Burgess et al., [@B10]) through mechanisms involving the attenuation of the inflammatory processes, as well as modulation of PPARγ signaling (Ndisang, [@B54]). Furthermore, chronic HMOX1 induction was shown to increase metabolic turnover, heat production, and physical activity in an experimental model of obesity (Csongradi et al., [@B14]), suggesting the complexity of the beneficial effects of HMOX1 induction upon these metabolic disorders.

Heme Oxygenase and Diabetes -- Clinical Evidence
================================================

Experimental data on the role of HMOX in the pathogenesis of diabetes, metabolic syndrome, and obesity are also supported by the clinical evidence. Plasma concentrations of HMOX1 have been demonstrated to strongly correlate with type 2 diabetes mellitus (Bao et al., [@B5]). In fact, subjects in the highest quartile of HMOX1 plasma levels had more than an 8X higher risk for development of type 2 diabetes, compared to the lowest quartile (Bao et al., [@B5]). In this study, the HMOX1 plasma level might reflect increased oxidative stress preceding the expression of diabetes. In addition, it is known that high glucose exposure leads to HMOX1 induction (Jonas et al., [@B31]; Won et al., [@B86]), which also might account for the observed phenomenon. On the other hand, the same authors recently published a meta-analysis of six studies focused on the role of *HMOX1* promoter gene variants and the risk of diabetes, covering almost 2,000 diabetic patients and 3,500 controls. These results revealed that subjects carrying longer (GT)n repeats in the *HMOX1* gene promoter (associated, nevertheless, with decreased HMOX1 activity), had an increased risk of type 2 diabetes (Bao et al., [@B4]). In addition to the effect on diabetes risk, diabetic subjects with the L/L genotype had an almost threefold increase in CVD risk, even after controlling for conventional risk factors in one of the studies involved in the reported meta-analysis (Chen et al., [@B11]). Further detailed clinical studies are needed to elucidate all of the mechanisms related to the roles of HMOX in the risks of development of diabetes.

Biliverdin Reductase and Diabetes -- Experimental Evidence and Possible Clinical Implications
=============================================================================================

Biliverdin reductase, similarly as HMOX, is an evolutionarily conserved enzyme, responsible for the hydrogenation of biliverdin on bilirubin. Besides that, BLVRA has multiple other functions affecting cell signaling, modulating immune system response, and also exerting substantial metabolic effects (Maines, [@B47]; Kapitulnik and Maines, [@B33]; Wegiel et al., [@B85]). BLVRA also serves as a unique serine/threonine/tyrosine kinase, significantly modulating (among other molecules) the phosphorylation of the insulin receptor substrate-1, as well as other insulin/IGF-1 signaling pathway targets (Kapitulnik and Maines, [@B33]). As a result, BLVRA diminishes insulin signaling, and acts as a negative regulator of glucose uptake (Lerner-Marmarosh et al., [@B41]). BLVRA also binds to the p85 regulatory subunit of PI3K/Akt (Pachori et al., [@B64]), a mechanism which might also lead to improved insulin sensitivity (Terauchi et al., [@B76]). Based upon this data, small BLVRA-based peptides which activate the insulin receptor signaling axis have been suggested as possible therapeutics to combat insulin resistance in diabetic patients (Lerner-Marmarosh et al., [@B40]).

Not only BLVRA itself, but also the products of its basic enzymatic activity, biliverdin (and consequently bilirubin), might significantly contribute to protection from diabetic complications. Oral administration of biliverdin to *db/db* mice partially prevented a worsening of hyperglycemia and glucose intolerance (Ikeda et al., [@B28]), as well as diabetic nephropathy in these animals, principally *via* inhibition of oxidative stress-induced damage, mediated by the interference with the NADPH oxidase pathway (Fujii et al., [@B18]). Biliverdin-treated animals had less albuminuria, and complete protection against the progression of mesangial expansion, accompanied by normalization of transforming growth factor-β1 and the expression of fibronectin (Fujii et al., [@B18]).

There are no clinical data on the role of BLVRA/biliverdin in diabetes, metabolic syndrome, or obesity. Only recently, a paper describing the effect of a BLVRA gene variant (rs699512) on the risk of essential hypertension has just been reported (Lin et al., [@B46]). Detailed studies are certainly needed to fully elucidate the clinical relevance of the experimental findings discussed.

Bilirubin and Diabetes -- Experimental Evidence
===============================================

It is not surprising that bilirubin, a subsequent reduction product of biliverdin, also has salutary effects in terms of the prevention of diabetes mellitus and its complications. In addition, bilirubin was also reported to provide protection against metabolic syndrome, and to be negatively associated with overweight and obesity.

In fact, in a manner similar to biliverdin substantially improving renal pathology in *db/db* mice, specifically *via* inhibition of NADPH oxidase (as discussed above), a practically identical effect was observed in hyperbilirubinemic Gunn rats exposed to streptozocin (Fujii et al., [@B18]). Compared to their diabetic normobilirubinemic heterozygous siblings, diabetic Gunn rats developed less albuminuria, exhibited practically normal urinary levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), as well as 8-epi-prostaglandin F2α levels; both markers of systemic oxidative stress. Additionally, expression of NADPH oxidase was markedly attenuated in the kidneys of diabetic Gunn rats, who also exhibited complete inhibition of mesangial expansion when compared to normobilirubinemic diabetic controls (Fujii et al., [@B18]). Consistent with this data, Korean researchers reported substantial resistance of hyperbilirubinemic Gunn rats to developing diabetes after intraperitoneal exposure to streptozocin, compared to their normobilirubinemic littermates (Fu et al., [@B17]). Markers of diabetes, such as fasting blood glucose and HbA1c levels were much less pronounced in Gunn rats; on the other hand, insulin secretion by the pancreatic islets was preserved in hyperbilirubinemic animals. In addition, concentrations as low as 1.7 μmol/L bilirubin prevented streptozocin-induced apoptosis in rat insulinoma cell culture; significantly supporting the *in vivo* data (Fu et al., [@B17]).

Bilirubin, Diabetes, Metabolic Syndrome, and Obesity -- Clinical Evidence
=========================================================================

Negative associations between serum bilirubin concentrations and abnormal glucose tolerance tests were reported as early as 1996 (Ko et al., [@B35]). Since then, numerous clinical studies evaluating the possible associations between serum/plasma bilirubin levels and the risk of diabetes (and its complications) have been published. Inoguchi et al. ([@B29]) first indicated that diabetic patients who have concomitant Gilbert syndrome have a lower prevalence rate of vascular complications, compared to normobilirubinemic diabetics. Although not specifically mentioned in their study, the prevalence of Gilbert syndrome among more than 5,000 consecutive diabetics was at least three times lower than would be expected in the general population. This data is in line with our observation of low prevalence of diabetes in subjects with (TA)~7~ promoter variation in *UGT1A1* responsible for systemic bilirubin homeostasis (Jirásková et al., [@B30]), and with low levels of AGEs in Gilbert syndrome subjects, compared to the normobilirubinemic population (Kalousová et al., [@B32]). Furthermore, low serum bilirubin levels were identified as an important predictor of CVD in Type 2 diabetes patients receiving haemodialysis (Fukui et al., [@B20]). Just recently, another group of Japanese investigators reported in their cross-sectional study on more than 3,000 participants, that compared to subjects within the lowest bilirubin quartile, those with the highest bilirubin levels had a four times lower prevalence of diabetic retinopathy (Yasuda et al., [@B91]). In a large Korean cross-sectional study on almost 94,000 subjects, high serum bilirubin was also found to be associated with the reduced risk of diabetes mellitus and diabetic nephropathy (Han et al., [@B23]). Higher serum bilirubin levels were also shown to protect from diabetes mellitus in the US National Health and Nutrition Examination Survey (NHANES) on almost 16,000 subjects. In this study, subjects with a bilirubin level above 10 μmol/L had 20% less risk of developing diabetes, compared to those with bilirubin levels below this cut-off value, even after multiple adjustments (Cheriyath et al., [@B12]).

Similarly, additional studies have supported the protective effects of bilirubin on both clinical and laboratory outcomes of diabetic subjects. Serum bilirubin concentrations were demonstrated to be negatively associated with albuminuria in patients with type 2 diabetes (Fukui et al., [@B19]), HbA1c levels (being an independent risk factor of CVD) in Japanese populations (Oda, [@B61]; Oda and Kawai, [@B62]; Ohnaka et al., [@B63]); additionally, with both insulin resistance and prevalence rate of the metabolic syndrome among children and adolescents (Lin et al., [@B44]), as well as in adult populations (Kwon et al., [@B36]; Wu et al., [@B89]). Consistent with this data, low prevalence of metabolic syndrome in subjects with phenotypic Gilbert syndrome was described in a recent large Korean study on more than 12,000 participants (Choi et al., [@B13]).

In line with these negative relationships between serum bilirubin levels and metabolic syndrome, a negative association between bilirubin levels and abdominal obesity *per se* has been shown in several recent studies (Bhuiyan et al., [@B8]; Lin et al., [@B44]; Choi et al., [@B13]; Kwon et al., [@B36]; Wu et al., [@B89]). Since weight reduction is known to reduce several cardiovascular risk factors, it is important to note that each one percent decrease in weight loss was associated with a linear increase in serum bilirubin concentration (Andersson et al., [@B2]). The close relationship between serum bilirubin levels and the *UGT1A1* gene promoter variants, responsible for manifestation of Gilbert syndrome in Asians, and the risk of non-alcoholic fatty liver disease (a condition commonly associated with obesity and metabolic syndrome) was recently demonstrated in Taiwanese children (Lin et al., [@B45]); further underlining the importance of the heme catabolic pathway in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus and its complications.

Pharmacologic and/or Nutraceutic Interventions
==============================================

Interventions which induce HMOX1 and/or BLVRA, or those that inhibit UGT1A1 activities might be effective in increasing serum and tissue bilirubin concentrations, as well as in modulating signaling pathways involved in energy homeostasis.

Heme oxygenase 1, as a highly inducible enzyme, which can be upregulated by many common drugs routinely used in clinical medicine (Bach, [@B3]), including non-steroidal anti-inflammatory drugs, hypolipidemics (Muchová et al., [@B53]; Wu et al., [@B87]), PPARα agonists, certain immunosuppressive drugs, to mention just a few. It is likely that at least part of their therapeutic action might be mediated *via* induction of HMOX1. The therapeutic potential of HMOX1 induction is also supported by recent experimental data demonstrating that chronic HMOX1 induction lowers body weight, corrects hyperglycemia and hyperinsulinemia, as well as increases oxygen consumption, heat production, and activity in obese mice (Csongradi et al., [@B14]).

Based on recent data, it also becomes evident that BLVRA might have great therapeutic implications (Maines, [@B48]). In fact, small residue peptides designed according to the primary structure of BLVRA were shown to block important pathways implicated in the pathogenesis of diabetes, including the inhibition of the MAPK (Lerner-Marmarosh et al., [@B40]) and TNF-α/PKC ζ/NF-κB pathways (Lerner-Marmarosh et al., [@B39]), as well as the inhibition of activation and membrane translocation of PKC-βII (Maines et al., [@B49]). There are also pharmaceuticals capable of a partial inhibition of UGT1A1, which in turn result in a mild elevation of systemic bilirubin levels. Among the substances having UGT1A1 inhibiting activity is a uricosuric drug probenecid (McCarty, [@B51]), and also the antiviral drug atazanavir (Dekker et al., [@B15]). In fact, atazanavir has been demonstrated to improve endothelial function in patients with type 2 diabetes mellitus, most likely due to its bilirubin-increasing activities (Dekker et al., [@B15]).

However, the heme catabolic pathway might also be potentiated through non-pharmacologic means, and its salutary effects can, for instance, be mimicked by tetrapyrollic compounds widely occurring in plants and algae. There are numerous natural HMOX1 inducers originating from plants, including polyphenols, but also compounds such as curcumin, or silymarin (Bonifaz et al., [@B9]). Indeed, curcumin was reported to increase insulin secretion from rat-isolated pancreatic islets *via* HMOX1 induction (Abdel Aziz et al., [@B1]), as well as to improve clinical and laboratory markers of experimental diabetes (Gutierres et al., [@B22]; Soetikno et al., [@B72]); the same effect was also demonstrated for silymarin-treated diabetic rats (Vessal et al., [@B79]). Although the action of both compounds is certainly multifactorial, HMOX1 induction seems to play an important role in their anti-diabetic effects.

It is also tempting to speculate that oral supplementation with nutraceuticals containing plant tetrapyrolles, such as phycocyanobilins (Lee et al., [@B38]; Moura et al., [@B52]), or their increased consumption in the form of natural foods (Tonstad et al., [@B77]) might be used as a novel approach of the chemoprevention of obesity, metabolic syndrome, and diabetes.

Concluding Remarks
==================

In this review, the experimental as well as clinical studies on the associations between CVD, diabetes mellitus, metabolic syndrome, and obesity with the heme catabolic pathway have been discussed. These studies unanimously show that low serum bilirubin concentrations are associated with an increased risk of these pathologic conditions; whereas, mildly elevated serum bilirubin levels provide protection. Moreover, it is clear that apart from the direct beneficial effects of bile pigments, the enzymes HMOX1 and BLVRA also play an important role in the development of these metabolic diseases. Based on recent data, it seems that there is a therapeutical potential to modulate HMOX1, BLVRA, and UGT1A1 activities, and/or mildly increase bilirubin levels (or its analogs) in the systemic circulation to suppress pathways leading to the development of diabetes and its complications. Obviously, detailed studies to explore this potential further appear warranted, and will definitely provide much needed evidence that the whole heme catabolic pathway is also likely beneficial for this group of metabolic diseases.
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